Navigation Links Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity

ALBANY, New York, September 4, 2013 /PRNewswire/ --

New Report Added in ResearchMoz Reports Database Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity

ResearchMoz announces that it has published a new study Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity

Researchmoz, the leading business intelligence added new report to its vast collection. "Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity". Obesity is often described as a global endemic, with incidence dramatically increasing over the past decades, particularly in developed countries. Being overweight or obese is a major risk factor in the development of many chronic diseases, including cardiovascular diseases, cancer, and diabetes, of which treatment incurs extensive economic and healthcare costs. Numerous anti-obesity drugs have been approved in the past decade, including Knoll Pharmaceutical's Meridia (sibutramine) and Acomplia (rimonabant), only for them to be removed from the market due to evidence of suicidal thoughts, depression and cardiovascular problems with their long-term use. As such, healthcare professionals have a negative perception of such drugs and do not widely prescribe them, a major barrier to the growth of the anti-obesity therapeutics market. Only orlistat is currently deemed safe for the long-term treatment of obesity; being proven to produce a placebo-adjusted weight-loss average of a limited 3kg. Two anti-obesity drugs were approved in June and July 2012, and A strong enough safety and efficacy (average placebo-adjusted weight loss of 5kg at the medium dose) profile to make a significant impact on the market, providing it is proven safe in long-term-use studies. If proven safe, GBI Research expects the sales of Qsymia and other drugs expected to be approved over the forecast period to increase the market size to $2.7 billion. Although moderate, this is significantly below the market potential given the size of the prevalence population. Optimally safe and effective anti-obesity drugs which overcome healthcare professionals' negative opinions will have to be developed if the size of the market is ever to reflect the prevalence of obesity.

Browse Complete Report with TOC@


The report analyzes the incidence of obesity, current treatment options, pipeline and market forecasts, and deals surrounding anti-obesity drugs.

The report includes:

• A brief introduction to obesity; detailed analysis of recent, current and projected incidence trends; co-morbidities; economic implications of their treatment; and the current treatment options

• Analysis of the currently marketed anti-obesity drugs, including recent sales figures, safety and efficacy data, and a discussion of each drug's expected performance within the forecast period

• Comprehensive reviews of the pipeline for anti-obesity drugs, including analysis by molecule type and mechanism of action

• Statistical analysis of clinical trial duration, size, and failure rate by Phase and molecule type

• An in-depth forecast model for the anti-obesity drugs market in the US, UK, France, Germany, Italy, Spain and Japan. Each model is based on the anticipated market performance of marketed drugs and those expected to be approved within the forecast period, and takes into account drug cost, efficacy, safety, and likely prescription volumes.

• A detailed discussion of the drivers and barriers for this immature market

Reasons to Buy

The report will enhance your decision-making capability by allowing you to:

• Understand the large number of potential molecular targets for the development of an anti-obesity drug, as well as the strengths, weaknesses, and risks of each drug type

• Gain an in-depth view of the current status of the anti-obesity drug pipeline, including the most common molecular targets and molecule types in development

• Observe the trends in clinical trial duration and size by Phase, molecule type and mechanism of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and future developmental programs

• Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the anti-obesity drugs market

• Analyze current and past deals surrounding anti-obesity drugs, including their value, year of deal and in depth details of the highest value deals

Popular Market Research Reports Report:

Power Rental Market: Many companies that deal in a wide  variety of industries are using power rentals to fulfill their temporary  power requirements. These companies hire a wide range of power  equipment and power services from rental companies to fulfill their  power needs without investing huge amounts for such equipment and  services. This helps these companies in reducing their overall cost of initial investment and saves them from making long term investments.  Many companies are now coming forward  to supply power on rent, thereby increasing the quality of service in  power rentals, which is ultimately enhancing the confidence of buyers in  purchasing energy on rent. Browse Complete Report@

Business Process Management(BPM) Market: Research announces that it has a new study on Business Process Management (BPM) Software Market Shares and Forecasts, Worldwide, 2011-2017. The 2011 study has 775 pages, 245 tables and figures. Business Process Management, (BPM) is evolving more sophisticated software that works in cloud computing environments, allowing users at every level to achieve self-provisioning and automate processes that involve collaboration.IBM is the market leader in BPM with a suite of products that improve every year. IBM is able to invest in the product set, improving it as the customer base grows ever larger, spreading the cost of software implementation across the large customer base. Browse Complete Report@

Global Pet Food Market  : Analysts forecast the Global Pet Food market to grow at a CAGR of 6.35 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in urbanization which has increased the purchasing power of people. The Global Pet Food market has also been witnessing a rise in the number of nuclear families. However, health issues faced by pets often restrict people from keeping pets in their homes and could pose a challenge to the growth of this market. Browse Complete Report@

Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Etiology and Pathophysiology
2.2 Classification
2.3 Epidemiology
2.3.1 The US
2.3.2 Obesity in the Top Five European Markets
2.3.3 Japan
2.4 Comorbidities
2.4.1 Type 2 Diabetes
2.4.2 Hypertension
2.4.3 Dyslipidemia
2.4.4 Respiratory Problems
2.4.5 Osteoarthritis
2.4.6 Cancer Risk
2.5 Economic Burden
2.6 Current Therapy Options
2.6.1 Lifestyle and Behavioral Modifications
2.6.2 Bariatric Surgery
2.6.3 Pharmacotherapy
2.6.4 Treatment Algorithms and Prescription Habits
2.6.5 Method of Determining Treatment Effectiveness
2.7 Why Develop Therapeutic Anti-obesity Drugs?
2.8 GBI Research Report Guidance

3 Marketed Products
3.1 Amphetamine-like Drugs
3.1.1 Overview
3.1.2 Efficacy Profile
3.1.3 Safety Profile
3.2 Qsymia, Vivus, Inc.
3.2.1 Overview
3.2.2 Efficacy Profile
3.2.3 Safety Profile
3.2.4 Discussion
3.3 Orlistat
3.3.1 Overview
3.3.2 Efficacy Profile
3.3.3 Safety Profile
3.3.4 Discussion
3.4 Belviq, Arena Pharmaceuticals
3.4.1 Introduction
3.4.2 Efficacy Profile
3.4.3 Safety Profile
3.4.4 Discussion
3.5 Low Long-term Success Rate of Marketed Anti-Obesity Drugs
3.6 Discussion

4 Pipeline
4.1 Overview of Pipeline by Phase, Molecule Type and Molecular Target
4.2 Clinical Trial Duration and Size
4.2.1 Clinical Trial Duration
4.2.2 Clinical Trial Size
4.3 Clinical Trial Failure, Attrition Rate and Reasons for Clinical Trial Failure
4.4 Primary and Secondary Endpoints
4.5 Late-stage Drugs of the Developmental Pipeline
4.5.1 Contrave, Orexigen Therapeutics
4.5.2 Cametor, Norgine BV
4.5.3 Victoza, Novo Nordisk
4.5.4 Tesofensine (NeuroSearch)
4.6 Discussion

5 Market Forecasts
5.1 Global Market
5.2 The US
5.2.1 Epidemiology and Treatment Usage Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Size
5.3 Europe
5.3.1 Treatment Usage Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 Japan
5.4.1 Treatment Usage Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Forecast
5.5 Discussion
5.6 Drivers and Barriers of the Anti-obesity Market
5.7 Obesity Market Drivers
5.7.1 Obesity is a Very Prevalent Disease with Large Potential Target Populations Globally
5.7.2 Recent Approval of Qsymia to Drive Market Growth Providing its Long-term Safety is Proved
5.7.3 Diversification of Molecular Targets
5.8 Obesity Market Barriers
5.8.1 Low Treatment Rate
5.8.2 Reimbursement Issues

6 Licensing and Co-Development Deals
6.1 Licensing Deals
6.1.1 EMD Serono Enters into Collaboration and Licensing Agreement with Theratechnologies
6.1.2 Amylin Pharma Enters into Licensing Agreement with Takeda Pharma
6.1.3 Palatin Technologies Extends License Agreement with AstraZeneca
6.1.4 Zealand Pharma Enters into Licensing and Collaboration Agreement with Boehringer

6.2 Co-development Deals
6.2.1 Isis Enters into Collaboration Agreement with Ortho-McNeil
6.2.2 Orexigen Therapeutics Enters into Co-development Agreement with Takeda Pharma for

7 Appendix
7.1 References
7.2 Abbreviations
7.3 All Pipeline Drugs by Phase
7.3.1 Discovery
7.3.2 Preclinical
7.3.3 Phase I
7.3.4 Phase II
7.3.5 Phase III
7.3.6 Pre-Registration
7.4 Market Forecasts to 2019
7.4.1 Global
7.4.2 The US
7.4.3 UK
7.4.4 France
7.4.5 Germany
7.4.6 Italy
7.4.7 Spain
7.4.8 Japan
7.5 Methodology
7.6 Secondary Research
7.7 Therapeutic Landscape
7.8 Epidemiology-Based Forecasting
7.9 Market Size by Geography
7.10 Pipeline Analysis
7.11 Contact Us
7.12 Disclaimer

Browse Complete Report with TOC@

About Us

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-997-4948


SOURCE ResearchMoz
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ResearchMoz.US: Direct to Consumer (DTC) Advertising in Pharmaceuticals - Shift From Traditional Mass-Media Platforms Towards Personalization via Online and Social Media- Market Research Report
2. Biotechnology Market By Application (Biopharmacy, Bioservices, Bioagri, Bioindustrial), By Technology (Fermentation, Tissue Regeneration, PCR, Nanobiotechnology, DNA Sequencing & Others) - Global Industry Analysis, Size, Share, Growt
3. Obesity journal publishes new study on lorcaserin, a weight-loss medication recommended for approval by FDA advisory panel
4. Obesity Care Continuum (OCC) Applauds FDA for Approval of New Obesity Drug
5. Takes Aim at Youth Obesity, Set to Launch Youth Fitness Equipment
6. Top Ten Obesity Risks Infographic
7. Concordia Study Indicates Obesity is Becoming the Nations Top Health Issue
8. Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
9. Unigene To Present at the 2012 Obesity Societys 30th Annual Scientific Meeting
10. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
11. seca Takes the Right Measures to Combat Childhood Obesity
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  "They really did ... of her Kaiser Permanente care team, after a routine ... treatment plan for cancer. The 79-year-old Kaiser Permanente Senior ... , went in for what she thought was tendinitis ... physician and care team, however, she was diagnosed with ...
(Date:10/8/2015)...  Trovagene, Inc., (NASDAQ:   TROV) a developer ... of results from a field experience analysis featuring ... (PCM) platform to accurately identify mutational status, ... appropriate therapy for patients. Mark Erlander , ... the results today in an oral presentation titled ...
(Date:10/8/2015)... York , October 8, 2015 ... Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 ... valued at USD 2.63 billion in 2013 and is anticipated ... 2022 to reach USD 4.00 billion in 2022. --> ... Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - ...
Breaking Medicine Technology:
... Calif., May 17, 2012   Accuray Incorporated (Nasdaq: ... announced today the appointment of Richard Pettingill, LFACHE as ... May 11, 2012.   Richard Pettingill,s career ... leadership positions in a variety of prominent organizations. Most ...
... 2012 Simbionix USA Corporation, the ... education products, is proud to announce the release ... GI Mentor™ Express simulator and the ...      (Logo: ...
Cached Medicine Technology:
(Date:10/9/2015)... , ... October 09, 2015 , ... ... their “Agents of Change” program, a community improvement initiative that involves working with ... to benefit from the assistance of Confidence Plus Insurance is the Gleason Park ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... ... States, is welcoming individuals from all walks of life to save money on ... set price of $25 per month per medication, individuals and families can receive ...
(Date:10/9/2015)... Nashville, TN (PRWEB) , ... October 09, 2015 , ... ... to announce their partnership as MD Anderson prepares to go-live on the Epic platform ... effort planned for early 2016. Santa Rosa will execute the contract by supporting Scheduling ...
(Date:10/9/2015)... Maryland (PRWEB) , ... October 09, 2015 , ... ... and assisted living placement counseling, recently opened its newest office in Maryland – ... senior care industry with a background as a project management technology consultant to ...
(Date:10/9/2015)... ... October 09, 2015 , ... BrightStar ... recognized by Cabarrus County Active Living and Parks for its outstanding commitment to ... company’s dedication to consistently going above and beyond the call of duty, seniors ...
Breaking Medicine News(10 mins):
... for those with scent-robbing viral infection, study found , ... people who lose their sense of smell after a ... 15 patients with post-viral olfactory dysfunction (PVOD) had 10 ... were compared with PVOD patients treated with vitamin B ...
... activity in depressed and anxious people indicates that some of ... or for worse by anxiety. The study, in ... at depression and two types of anxiety: anxious arousal, the ... better known as worry. The researchers used functional Magnetic ...
... Damaka ... platforms , ... TX (PRWEB) April 1, 2010 -- Damaka, a technology pioneer in Mobile Unified ... 2-way Video, Application Sharing) Sweeping™ between laptops and mobile devices earlier in May 2009. ...
... ... Town Plaque of Honor for Excellence in Customer Satisfaction for the second year in a row. ... local business based on customer reviews found on the Internet’s most respected user review websites. ... Minneapolis, MN (PRWEB) April 1, ...
... first study of its kind, 161 postnatal women with ... groups to test the effect of a physiotherapist-led exercise ... group received an eight-week "Mother and Baby" program, including ... with parenting education. In the second group, ...
... at the University of Delaware have developed a new ... Alzheimer,s, and other diseases., Developed by Zhihao Zhuang, UD ... group, the chemical method yields hundredsfold more ubiquitylated proteins ... to revealing such mysteries as how cancer cells gain ...
Cached Medicine News:
... ideal where space is restricted. Due to ... and flexible in every situation. For many ... be positioned optimally on the JUPITER during ... the operating theatre, the high level of ...
... schaerer axis 800 operating ... designed for those disciplines ... access. The stability, the ... the offset positioned telescoping ...
... words "mobile operating table" literally! The Alphastar 1132 ... of a general purpose operating table - is ... operations, a cable connected hand control, an IR-hand ... there is a control panel at the top ...
... introduce the Cmax operating table that combines ... surgical table with the radiolucence and precise ... the most advanced, versatile surgical table on ... to support advancements in surgical procedures and ...
Medicine Products: